References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. DOI: 10.3322/caac.21551. Epub 2019 Jan 8. PMID: 30620402.
- Quintana L, Ward A, Gerrin SJ, et al. Gleason misclassification rate is independent of number of biopsy cores in systematic biopsy. Urology. 2016;91:143–149. DOI: 10.1016/j.urology.2015.12.089.
- Kelly SP, Anderson WF, Rosenberg PS, Cook MB. Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur Urol Focus. 2018;4:121–127. DOI: 10.1016/j.euf.2017.10.014.
- Ramirez D, Gupta A, Canter D, et al. Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. BJU Int. 2016;117:783–786. DOI: 10.1111/bju.13345.
- Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. DOI: 10.3322/caac.21763. PMID: 36633525.
- Shephard EA, Stapley S, Neal RD, Rose P, Walter FM, Hamilton WT. Clinical features of bladder cancer in primary care. Br J Gen Pract. 2012;62:598–604. DOI: 10.3399/bjgp12X654560.
- Cutaia G, Tosto G, Cannella R, et al. Prevalence and clinical significance of incidental findings on multiparametric prostate MRI. Radiol Med. 2020;125(2):204–213. DOI: 10.1007/s11547-019-01106-9. Epub 2019 Nov 29. PMID: 31784928.
- Verma S, Rajesh A, Prasad SR, Gaitonde K, Lall CG, Mouraviev V. Urinary bladder cancer: Role of MR imaging. Radiographics. 2012;32:371–387. DOI: 10.1148/rg.322115125.
- Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 Update. J Urol. 2007;178:2314–2330. DOI: 10.1016/j.juro.2007.09.003.
- Panebianco V, Narumi Y, Altun E, et al. Multiparametric magnetic resonance imaging for bladder cancer: Development of VI-RADS. Eur Urol. 2018;74(3):294–306. DOI: 10.1016/j.eururo.2018.04.029.
- Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic performance of MRI for prediction of muscle-invasiveness of bladder cancer: A systematic review and meta-analysis. Eur J Radiol. 2017;95:46–55. DOI: 10.1016/j.ejrad.2017.07.021.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. DOI: 10.3322/caac.21492.
- Sherrer RL, Lai WS, Thomas JV, Nix JW, Rais-Bahrami S. Incidental findings on multiparametric MRI performed for evaluation of prostate cancer. Abdom Radiol (NY). 2018;43:696–701. DOI: 10.1007/s00261-017-1237-x.
- Rayn KN, Hale GR, Bloom JB, et al. Incidental bladder cancers found on multiparametric MRI of the prostate gland: A single center experience. Diagn Interv Radiol. 2018;24(5):316–320. DOI: 10.5152/dir.2018.18102. PMID: 30211685; PMCID: PMC6135055.
- Wagnerova M, Macova I, Hanus P, et al. Quantification and significance of extraprostatic findings on prostate MRI: A retrospective analysis and three-tier classification. Insights Imaging. 2023;14:215. DOI: 10.1186/s13244-023-01549-9.
- Eryuruk U, Tasdemir MN, Aslan S. Comparison of the diagnostic performance of biparametric and multiparametric MRI in detecting muscle invasion of bladder cancer located at the ureteral orifice. Abdom Radiol (NY). 2023. DOI: 10.1007/s00261-023-03979-x. Epub ahead of print. PMID: 37328615.
- Morris DS, Weizer AZ, Ye Z, Dunn RL, Montie JE, Hollenbeck BK. Understanding bladder cancer death. Cancer. 2009;115:1011–1020. DOI: 10.1002/cncr.24136.